Tirzepatide, the first single-molecule, dual GIP and GLP-1 receptor agonist, is licensed in the UK for the treatment of both type 2 diabetes and obesity, and has been demonstrated to slow gastric emptying, increase insulin sensitivity and glucose-dependent insulin secretion, and decrease glucagon secretion and appetite
PlexusDx compounded tirzepatide from licensed 503A pharmacies offers the same active ingredient at lower cost without insurance requirements
And, for what its worth, there is some data to suggest yerba mate may be associated with losing weight: It stimulates lipolysis, the breakdown of fats, according to 2019 research in the Brazilian Journal of Pharmaceutical Sciences
PMID: 30646146, PMCID: PMC6324513, DOI: 10.1001/jamanetworkopen.2018.2044